A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects With Systemic Lupus Erythematosus.

Trial Profile

A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects With Systemic Lupus Erythematosus.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Anifrolumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Acronyms MUSE
  • Sponsors MedImmune
  • Most Recent Events

    • 17 Jun 2017 Results of Exposure-Response analysis, presented at the 18th Annual Congress of the European League Against Rheumatism
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
    • 17 Jun 2017 Results of post-hoc analysis assessing lupus low disease activity state presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top